Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
01
02
2023
received:
07
11
2022
accepted:
20
02
2023
medline:
12
4
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well-established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival. A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicenter, retrospective cohort analysis. Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p < 0.001). Depth of response impacted survival outcomes: two-year predicted PFS rates after achieving CR/VGPR vs PR were 96% versus 82%, respectively (p = 0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000 mg/m
Substances chimiques
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
750-759Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Swerdlow SH, Cook JR, Sohani AR, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues Revised. 4th ed. IARC; 2017:232-235.
Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27(9):1492-1501.
Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7(11):e827-e837.
Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv41-iv50.
Buske C, Seymour JF. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015;56(9):2489-2490.
Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5(7):e299-e309.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018;181(1):77-85.
Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018;97(8):1417-1425.
Abeykoon JP, Zanwar S, Ansell SM, et al. Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2019;37(15_suppl):7509.
Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124(9):1404-1411.
Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the eighth international workshop on Waldenström's Macroglobulinemia. Blood. 2016;128(10):1321-1328.
Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update. Leuk Lymphoma. 2016;57(4):766-782.
Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
Owen RG, Pratt G, Auer RL, et al. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol. 2014;165(3):316-333.
Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol. 2013;160(2):171-176.
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
Kastritis E, Dimopoulos MA. Disease control should be the goal of therapy for WM patients. Blood Adv. 2017;1(25):2483-2485.
Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011;154(2):223-228.
Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma. 2015;56(9):2637-2642.
Castillo JJ, Gustine J, Meid K, Dubeau T, Ghobrial IM, Treon SP. Lower doses of Bendamustine are not associated with lower response rates in previously untreated patients with Waldenström Macroglobulinemia. Blood. 2016;128(22):2969.
Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French innovative Leukaemia organization (FILO). Br J Haematol. 2019;186(1):146-149.
Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):133-135.
Castillo JJ, Gustine J, Dubeau T, et al. Deepening of response after completing rituximab-containing primary therapy in patients with Waldenstrom Macroglobulinemia. Blood. 2018;132(Suppl 1):2887.
Gaiolla R, Hartley S, Beech A, et al. Extended follow-up of CD4+ T cell recovery kinetics in a large cohort of patients with B-cell lymphoproliferative disease treated with rituximab-bendamustine. Hematol Oncol. 2021;39(1):137-140.
Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022;36(2):532-539.